Fractyl Health’s mission is to cure metabolic diseases by addressing their root cause: insulin resistance. The company has developed an innovative minimally invasive outpatient approach to treat insulin resistance with a medical device. The device is designed to rejuvenate the lining of the duodenum which leads to a significant decrease in insulin resistance. Currently, the device targets patients with type 2 diabetes, polycystic ovarian syndrome (PCOS) and nonalcoholic steatohepatitis (NASH).
Fractyl’s device is a treatment of the underlying disease and not just its symptoms. Clinical trials are being held in various locations around the world, with promising results, and commercialization has started in Europe.